New tumor cases show common gene therapy tool can come with risk - STAT
Source: STAT ·
New tumor cases show common gene therapy tool can come with risk STATFDA probes tumour risk tied to Novartis gene therapy ReutersNovartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details Fierce PharmaNovartis reports cases of tumours in children following treatment with Zolgensma SWI swissinfo.chSeven new tumor cases reported among patients on Novartis’…
From the source
- EnglishUnited States - Deutsch - English - Español - Français - Italiano - All languages - Afrikaans - azərbaycan - bosanski - català - Čeština - Cymraeg - Dansk - Deutsch - eesti - EnglishUnited Kingdom - EspañolEspaña - EspañolLatinoamérica - euskara - Filipino - FrançaisCanada - FrançaisFrance - Gaeilge - galego - Hrvatski - Indonesia - isiZulu - íslenska - Italiano - Kiswahili - latviešu - lietuvių - magyar - Melayu - Nederlands - norsk - o‘zbek - polski - PortuguêsBrasil - PortuguêsPortugal - română - shqip - Slovenčina - slovenščina - srpski (latinica) - Suomi - Svenska - Tiếng Việt - Türkçe - Ελληνικά - беларуская - български - кыргызча - қазақ тілі - македонски - монгол - Русский - српски - Українська - ქართული - հայերեն - עברית - اردو - العربية - فارسی - አማርኛ - नेपाली - मराठी - हिन्दी - অসমীয়া - বাংলা - ਪੰਜਾਬੀ - ગુજરાતી - ଓଡ଼ିଆ - தமிழ் - తెలుగు - ಕನ್ನಡ - മലയാളം - සිංහල - ไทย - ລາວ - မြန်မာ - ខ្មែរ - 한국어 - 日本語 - 简体中文 - 繁體中文 - 繁體中文香港 - EnglishUnited States - Deutsch -…
BestAIBroker analysis
- Finance-aware sentiment: negative (-0.70 on a -1 to +1 scale).
- Event classification: OTHER.
- Market importance score: 26/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
- Symbols referenced: NVS.